These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33424615)

  • 21. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
    Ishiguro M; Kawasaki K; Suzuki Y; Ishizuka F; Mishiro K; Egashira Y; Ikegaki I; Tsuruma K; Shimazawa M; Yoshimura S; Iwama T; Hara H
    Neuroscience; 2012 Sep; 220():302-12. PubMed ID: 22710066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
    Hafez S; Hoda MN; Guo X; Johnson MH; Fagan SC; Ergul A
    Transl Stroke Res; 2015 Jun; 6(3):171-80. PubMed ID: 25683354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke.
    Kablau M; Kreisel SH; Sauer T; Binder J; Szabo K; Hennerici MG; Kern R
    Cerebrovasc Dis; 2011; 32(4):334-41. PubMed ID: 21921596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between uric acid and the risk of hemorrhagic transformation in patients with acute ischemic stroke: a systematic review and meta-analysis.
    Qian Y; Li N; Li Y; Tao C; Liu Z; Zhang G; Yang F; Zhang H; Gao Y
    Front Neurol; 2024; 15():1378912. PubMed ID: 39119562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
    Jiang Y; Fan X; Yu Z; Cheng C; Wang XS; Lo EH; Sun X; Wang X
    Neurosci Lett; 2015 Aug; 602():73-8. PubMed ID: 26149229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
    Lapchak PA; Araujo DM; Song D; Zivin JA
    Stroke; 2002 Jan; 33(1):147-52. PubMed ID: 11779904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
    García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF
    Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
    García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
    Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early ischemic blood brain barrier damage: a potential indicator for hemorrhagic transformation following tissue plasminogen activator (tPA) thrombolysis?
    Jin X; Liu J; Liu W
    Curr Neurovasc Res; 2014; 11(3):254-62. PubMed ID: 24875486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of antidepressants in animal models of ischemic stroke: a systematic review and meta-analysis.
    McCann SK; Irvine C; Mead GE; Sena ES; Currie GL; Egan KE; Macleod MR; Howells DW
    Stroke; 2014 Oct; 45(10):3055-63. PubMed ID: 25184357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
    Liu H; Wang Y; Xiao Y; Hua Z; Cheng J; Jia J
    Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.
    García-Yébenes I; Sobrado M; Zarruk JG; Castellanos M; Pérez de la Ossa N; Dávalos A; Serena J; Lizasoain I; Moro MA
    Stroke; 2011 Jan; 42(1):196-203. PubMed ID: 21106952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resveratrol has an Overall Neuroprotective Role in Ischemic Stroke: A Meta-Analysis in Rodents.
    Liu J; He J; Huang Y; Hu Z
    Front Pharmacol; 2021; 12():795409. PubMed ID: 34987407
    [No Abstract]   [Full Text] [Related]  

  • 36. Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
    Zheng Y; Lieschke F; Schaefer JH; Wang X; Foerch C; van Leyen K
    Stroke; 2019 Dec; 50(12):3650-3653. PubMed ID: 31587659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke.
    Yu S; Liu X; Shen Y; Xu H; Yang Y; Ding F
    Neuroscience; 2016 Jul; 327():44-52. PubMed ID: 27060484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials.
    Pan X; Zhu Y; Zheng D; Liu Y; Yu F; Yang J
    Int J Stroke; 2015 Apr; 10(3):317-23. PubMed ID: 25545076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.
    Wang W; Li M; Wang Y; Li Q; Deng G; Wan J; Yang Q; Chen Q; Wang J
    Mol Neurobiol; 2016 Dec; 53(10):7028-7036. PubMed ID: 26671619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.